IDRI and Zydus sign agreement for development of IDRI's vaccine candidate for visceral leishmaniasis ( Infectious Disease Research Institute ) In a unique partnership, Zydus, India's fourth largest healthcare group and an innovation-led global healthcare provider, and IDRI, a Seattle-based non-profit research and product development organization, announced today they are collaborating on the production and clinical development of IDRI's visceral leishmaniasis vaccine candidate, designed to ...
July 25, 2013 - EurekAlert!
IDRI and Zydus Sign Agreement for Development of IDRI's Vaccine Candidate for Visceral Leishmaniasis (Kala-Azar) SEATTLE and AHMEDABAD, India, July 25, 2013 /PRNewswire-USNewswire/ -- In a unique partnership, Zydus, India's fourth largest healthcare group and an innovation-led global healthcare provider, and IDRI, a Seattle-based non-profit research and product development organization, announced today they are collaborating on the production and clinical development of IDRI's visceral leishmaniasis (VL ...
July 25, 2013 - PR Newswire via Yahoo! News